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Background: Rare genetic variation is an important class of autism spectrum disorder (ASD) risk factors and can
implicate biological networks for investigation. Altered serotonin (5-HT) signaling has been implicated in ASD, and
we and others have discovered multiple, rare, ASD-associated variants in the 5-HT transporter (SERT) gene leading
to elevated 5-HT re-uptake and perturbed regulation. We hypothesized that loci encoding SERT regulators harbor
variants that impact SERT function and/or regulation and therefore could contribute to ASD risk. The adenosine A3
receptor (A3AR) regulates SERT via protein kinase G (PKG) and other signaling pathways leading to enhanced SERT
surface expression and catalytic activity.
Methods: To test our hypothesis, we asked whether rare variants in the A3AR gene (ADORA3) were increased in
ASD cases vs. controls. Discovery sequencing in a case-control sample and subsequent analysis of comparison
exome sequence data were conducted. We evaluated the functional impact of two variants from the discovery
sample on A3AR signaling and SERT activity.
Results: Sequencing discovery showed an increase of rare coding variants in cases vs. controls (P=0.013). While
comparison exome sequence data did not show a significant enrichment (P=0.071), combined analysis
strengthened evidence for association (P=0.0025). Two variants discovered in ASD cases (Leu90Val and Val171Ile) lie
in or near the ligand-binding pocket, and Leu90Val was enriched individually in cases (P=0.040). In vitro analysis of
cells expressing Val90-A3AR revealed elevated basal cGMP levels compared with the wildtype receptor. Additionally,
a specific A3AR agonist increased cGMP levels across the full time course studied in Val90-A3AR cells, compared to
wildtype receptor. In Val90-A3AR/SERT co-transfections, agonist stimulation elevated SERT activity over the wildtype
receptor with delayed 5-HT uptake activity recovery. In contrast, Ile171-A3AR was unable to support agonist
stimulation of SERT. Although both Val90 and Ile171 were present in greater numbers in these ASD cases,
segregation analysis in families showed incomplete penetrance, consistent with other rare ASD risk alleles.
Conclusions: Our results validate the hypothesis that the SERT regulatory network harbors rare, functional variants
that impact SERT activity and regulation in ASD, and encourages further investigation of this network for other
variation that may impact ASD risk.
Keywords: Autism, Autism spectrum disorder, Serotonin, Serotonin transporter, Adenosine receptor, cGMP, DNA
sequencing, Rare variant, Single nucleotide polymorphisms (SNPs), Allelic association* Correspondence: james.s.sutcliffe@vanderbilt.edu
1Department of Molecular Physiology & Biophysics and Vanderbilt Brain Institute,
Vanderbilt University School of Medicine, Nashville, TN 37232-8548, USA
3Department of Psychiatry, Vanderbilt University School of Medicine,
Nashville, TN 37232-8548, USA
Full list of author information is available at the end of the article
© 2013 Campbell et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Campbell et al. Molecular Autism 2013, 4:28 Page 2 of 16
http://www.molecularautism.com/content/4/1/28Background
Serotonin (5-hydroxytryptamine (5-HT)) is a prominent
monoamine neurotransmitter in the central and peripheral
nervous systems, influencing mood, aggression, anxiety, im-
pulsivity, and other behaviors. Serotonergic signaling has
been implicated in multiple neuropsychiatric phenotypes,
including major depression, obsessive-compulsive disorder
(OCD), anxiety disorders, and autism spectrum disorder
(ASD), among others (reviewed in ref. [1]). The presynaptic,
antidepressant-sensitive 5-HT transporter (SERT; gene
symbol: SLC6A4) is a critical regulator of 5-HT signaling by
modulating synaptic 5-HT levels via presynaptic, Na+/Cl-
dependent re-uptake. Given the significance of SERT in
regulating 5-HT function and its targeting by widely used
medications, SLC6A4 has been an attractive target for
genetic studies in neuropsychiatric disorders. A significant
focus of SLC6A4 genetic studies is a common insertion/
deletion polymorphism (5-HTTLPR) in the promoter re-
gion reported to impact SLC6A4 gene expression [2]. Al-
though some evidence supports association of 5-HTTLPR
with psychiatric phenotypes including ASD, results overall
are mixed [3-5], potentially influenced by the inherent
difficulty of diagnosing behaviorally defined disorders and
heterogeneity within and across cohorts examined. Add-
itionally, single nucleotide variants (SNPs) within 5-
HTTLPR and the promoter region are inherent confounds
to many earlier studies [6-8].
The phenomenon of hyperserotonemia, or elevated
whole blood or platelet 5-HT seen in approximately 35%
of ASD cases, is the oldest ASD biomarker and is a
highly heritable trait [9]. The presence of SERT on the
platelet surface and its role in acquiring 5-HT from the
blood provides a plausible biological mechanism for SERT
involvement in hyperserotonemia [10-12]. Genetic associ-
ation related to SLC6A4 gene expression [13], as well as
an interaction of SLC6A4 with the gene encoding integrin
β3 (ITGB3), which physically interacts with SERT, sup-
ports this idea [14-16].
Following observations of significant genetic linkage at
17q11.2 (harboring SLC6A4) in multiplex ASD families
[17-19], we screened exons of SLC6A4 specifically in fam-
ilies contributing to the observed linkage and found mul-
tiple, novel coding variants (Ile425Leu, Phe465Leu, and
Leu550Val) and an elevated frequency of a previously
documented coding variant (Gly56Ala) to a degree that
profoundly deviated from expectations under Hardy-
Weinberg equilibrium [17]. Further support for a role of
these variants in ASD comes from studies reporting an
Ile425Val variant that segregated in pedigrees harboring
multiple psychiatric phenotypes, with Asperger syndrome
(an ASD), OCD, and other anxiety disorders being the
most prominent [20-22]. Functional characterization of
these SERT variants revealed that each elevated 5-HT
transport function, as well as altered protein kinase G(PKG) and p38 mitogen activated protein kinase (MAPK)
regulation [23,24]. Our characterization of one of these
variants (Gly56Ala) in knock-in transgenic mice revealed
elevated 5-HT clearance and p38 MAPK-dependent trans-
porter hyperphosphorylation in vivo accompanied by defi-
cits in the three classical behavioral domains associated
with ASD [25]. Collectively, these results suggest that al-
tered 5-HT signaling, and SERT activity and/or regulation
represents an important biological endpoint for the func-
tional impact of genetic variation at other genes contribut-
ing to SERT regulation and ASD risk.
Modulation of synaptic 5-HT is a dynamic and tightly
controlled process, subject to influence through multiple
signaling pathways and interacting proteins that act on
SERT (reviewed in [26]). Enhanced SERT activity can be
achieved via PKG and p38 MAPK signaling pathways acting
through trafficking-dependent and trafficking-independent
(that is, functional modulation) mechanisms. A trigger for
both of these uptake-enhancing pathways, and the focus of
this paper, is activation of the A3 adenosine receptor
(A3AR; gene symbol: ADORA3), a G-protein-coupled re-
ceptor (GPCR) that is expressed by 5-HT synthesizing neu-
rons at synaptic terminals [27,28]. A3ARs physically
interact and influence SERT [29] through a Gq-linked
stimulation of guanyl cyclase (GC)-mediated cGMP synthe-
sis. cGMP activation of PKG elevates SERT surface expres-
sion and, in parallel, a p38 MAPK-dependent elevation of
surface resident SERT proteins [26,28,30]. Importantly,
A3AR agonist stimulation of SERT is lost in A3AR knock-
out mice [30], providing evidence for the specificity of the
current tools used to study receptor/transporter coupling.
Given a role of A3ARs in SERT regulation, we targeted
ADORA3 as a candidate locus to determine whether rare
or common variants at this locus are correlated with ASD
risk and/or with altered A3AR-mediated SERT function or
regulation. To test for common allele effects on ASD risk,
single nucleotide polymorphisms (SNPs) that index com-
mon haplotypes at ADORA3 were assessed using family-
based association methods. The alternative rare variant
hypothesis was tested by Sanger sequencing of ADORA3
exons in a sample of ASD probands and ethnically
matched controls and followed by a replication analysis
using data from whole exome sequencing of independent
ASD cases and controls. Nonsynonymous variants identi-
fied as being increased in cases from these studies were
evaluated functionally through heterologous expression of
wildtype and variant A3ARs to test for changes in basal
and agonist-activated modulation of SERT activity.
Methods
Subjects
Sample for allelic association analysis
The sample for analysis of common alleles in this study
consisted of 958 combined simplex and multiplex ASD
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Vanderbilt University, Tufts-New England Medical Cen-
ter (including the Collaborative Linkage Study of Autism
(CLSA)) [31], or obtained from the NIMH Genetics
Repository (http://nimhgenetics.org). Samples from the
NIMH Repository were submitted by one of three groups:
the Autism Genetics Resource Exchange Consortium
(AGRE), University of Iowa (CLSA) [31], or Stanford Uni-
versity [32]. All ASD probands were assessed with the
Autism Diagnostic Interview (ADI) or its revision (ADI-R)
[33] and most with the Autism Diagnostic Observation
Schedule (ADOS) [34]. Affection status was assigned using
a classification scheme employed by the Autism Genome
Project [35] in which subjects were classified with either a
‘strict’ diagnosis if criteria for ‘autism’ were met on both
the ADI-R and ADOS, or a more inclusive ‘spectrum’ (that
is, ASD) diagnosis for subjects that met algorithm criteria
for (1) ‘autism’ on the ADI-R alone; (2) ‘ASD’ [36] on both
the ADI-R and ADOS; or (3) ‘autism’ on the ADOS alone.
Other ‘unaffected’ family members were designated as ‘un-
known’ for purposes of genetic analyses described below.
Demographic information for this sample is shown in
Additional file 1: Table S1. All studies were approved by
the Vanderbilt Institutional Review Board and with the in-
formed consent of participating families.
Genotyping and analysis of common alleles at ADORA3
To test for association of common alleles at ADORA3 in
ASD, we selected SNPs to represent all common haplotypes
(that is, ≥5%) across the transcriptional unit and flanking
sequence taking into account linkage disequilibrium pat-
terns. We used Haploview (http://www.broadinstitute.org/
haploview) [37] to analyze CEPH (CEU; Caucasian) SNP
data from the HapMap database (http://www.hapmap.org),
given that the vast majority of the sample was of European
ancestry. The Haploview implementation of Tagger identi-
fied tag-SNPs to capture common alleles across ADORA3
at an r2 ≥0.8 and minor allele frequency (MAF) ≥5%.
TaqMan™ allelic discrimination assays for four SNPs that
span 14.4 kb were obtained from Applied Biosystems
(ABI, Foster City, CA, USA) as Assays-on-Demand (AoD)
or designed as Assays-by-Design.
PCR amplification was conducted in a 5-μL volume in
accordance with manufacturer’s recommendations. In
brief, cycling conditions included an initial denaturation
at 95°C for 7 min, followed by 50 cycles of 92°C for 15 s
and 60°C for 1 min. Post-PCR allelic discrimination was
conducted using an ABI 7900HT genotypes ABI Sequence
Detection System software. Genotypes were checked for
completeness (≥98%) and conformity to expectations under
Hardy Weinberg Equilibrium (HWE). Other quality control
procedures included inter- and intra-plate replicates and
checks for Mendelian inconsistencies using PEDCHECK
[38]. Families containing Mendelian inconsistencies wereidentified and excluded from additional analysis. Family-
based allelic association testing was used to evaluate trans-
mission of alleles in the autism families being studied. Sin-
gle marker analysis was conducted using the family based
association test (FBAT) [39]. FBAT analysis was conducted
under the additive model, and significance was determined
using the empirical variance (−e) option, as this provides a
more conservative estimate of association, given the pres-
ence of multiplex families in the dataset. Statistical power
required to detect a meaningful association was determined
by power calculations using the Genetic Power Calculator
(http://pngu.mgh.harvard.edu/~purcell/gpc/) [40]. We as-
sumed ASD as a discrete trait with a prevalence of 1/100
and a sample size of 1,000 trios, further assuming MAFs of
5%, 10%, and 30%, respectively, and a D´=0.8. Based on
these calculations, we would have ≥80% power to detect
odds ratios (ORs) of ≥1.59, ≥1.44, and ≥1.36 for (risk) allele
frequencies of ≥5%, 10%, and 30%, respectively.
Determination of ancestry from genotype data
To permit association analysis within the major European
subset of the family-based sample and for subsequent
matching of cases and controls (see below), ancestry was
determined using STRUCTURE [41] and multidimen-
sional scaling (MDS) in PLINK [42] (http://pngu.mgh.har-
vard.edu/~purcell/plink) to analyze genome-wide parental
(founder) genotype data [35,43] from autism families.
Genome-wide (GW) genotypes were derived from differ-
ent platforms and in substantially different numbers.
Many multiplex families were genotyped by the Autism
Genome Project (AGP) in its Phase I linkage study using
the Affymetrix 10 k SNP platform [44], and 10 k data were
analyzed at that time using STRUCTURE. Other families
had genotypes from Illumina 550 k [43] and/or 1 M SNP
[35] arrays, and these were analyzed recently using MDS.
Fortuitously, numerous families had both sets of geno-
types and analyzed using both applications, and identical
ancestry classifications provided confirmation that both
STRUCTURE and MDS yielded consistent and robust
assignments that also agreed with self-report informa-
tion. A small number of families from the overall associ-
ation sample (1) did not have GW genotypes, in which
case self-report information determined classification or
(2) had neither GW genotype data nor self-report infor-
mation, in which case they were classified as being of
‘unknown’ ancestry.
Discovery and analysis of rare variants at ADORA3
Initial screening for sequence variants at ADORA3 uti-
lized whole blood derived DNA samples from 185 unre-
lated (predominantly Caucasian) cases (94% Caucasian;
5% African-American; 1% Hispanic). Non-clinical com-
parison samples were drawn from reference collections
and consisted of lymphoblastoid cell lines DNA from
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of the Coriell Human Genome Diversity Panel (http://
ccr.coriell.org/sections/Search/Panel_Detail.aspx?Ref=H
D100CAU&PgId=202); (2) 192 samples from the Hu-
man Random Control (HRC) collection corresponding
to subjects of European ancestry recruited in the UK
and obtained from Sigma-Aldrich (St. Louis, MO, USA;
http://www.sigmaaldrich.com/life-science/molecular-biol-
ogy/pcr/human-genomic-dna.html); and (3) 24 subjects
from the neurologically-normal NINDS/Coriell African-
American panel (http://ccr.coriell.org/Sections/Search/
Panel_Detail.aspx?Ref=NDPT111&PgId=202). Thus, the
comparison samples were 92% Caucasian and 8%
African-American. This discovery sample of cases and
controls provides 80% power to detect rare risk variants
of 0.1%, 0.5%, 1% allele frequencies with ORs of 16.2,
5.25, and 3.71, respectively. Our a priori expectation is
that functional ADORA3-containing, SERT-altering
functional variants would confer large genetic effects,
and thus we are reasonably powered under this assump-
tion. However, we would be significantly underpowered
if hypothetical rare variants conferred ORs <2.
PCR amplifying primers (Additional file 2: Table S2)
were designed using Primer3 (http://frodo.wi.mit.edu/
primer3/), and all potential amplicons were subjected to
a BLAST-Like Alignment Tool search to ensure no signifi-
cant matches existed elsewhere in the genome. Amplicons
were optimized using a gradient of annealing temperatures,
followed by agarose gel electrophoresis to determine ideal
annealing temperature. PCR was then performed on the
case (185) and control (305) screening samples. PCR re-
actions contained 7.1 nM of amplifying primers, 10 μL
of 2× Mastermix, and 12 ng of DNA in a final volume of
20 μL. ADORA3 primers were designed for exons 1 to 2
and >500 bp of promoter sequence. PCR amplification
conditions were 7 min at 95°C, 40 cycles of 15 s at 95°C,
12 s at the annealing temperature, and 60 s at 72°C, with a
final extension at 72°C for 7 min. Following PCR, each
product was examined by gel-electrophoresis, and once
verified for expected size and specificity, excess primers
and nucleotides were removed using Millipore 96 well filter
plates. Samples were quantitated, subjected to Sanger se-
quencing, and data analyzed for variants using Sequencher
v4.9 (Gene Codes Corporation, Ann Arbor, MI, USA).
Specific variants were confirmed by independent PCR
and sequencing, and for ASD cases with simultaneous
determination of segregation by inclusion of other avail-
able family members, affected or unaffected.
Variants were assessed using multiple approaches. We
noted whether or not they were previously documented
in dbSNP or the 1000 Genomes project. In silico algo-
rithms PolyPhen2 [45], SIFT [46], and SNAP [47] were
used to provide a bioinformatic estimate of whether amino
acid substitutions were likely to be ‘damaging’ or ‘nottolerated’ or benign. Cross-species conservation of the
amino acid residue and surrounding sequence was also
evaluated, along with available literature regarding struc-
tural features of the A3AR protein. Finally, to ask whether
there might be evidence to support a global burden of rare
(<1%) coding variants, the cohort allelic sums test (CAST)
was used. CAST is a grouping method in which the num-
ber of individuals with one or more variants in a gene is
compared between affected and unaffected individuals
[48,49]. Thus, we compared differences in rare allele
counts in matched cases and controls in a 2 × 2 contin-
gency table, and a Fisher’s Exact test was performed.
An independent replication sample for comparison to
variation identified in the discovery phase corresponded
to ASD cases and controls from the NIMH Repository.
Cases and controls were pair-matched for ancestry, and
samples used for whole exome sequence analysis as re-
cently described [50]. SLC6A4 coding variants (described
above) that affect SERT function and regulation are associ-
ated with not only ASD but also OCD, anxiety and mood
disorders [17,20,21]. Therefore, case-control pairs were
excluded if control subjects had any history of OCD or
anxiety disorders. Sequence data at ADORA3 for a total of
339 case-control pairs were examined for ‘functional’ (that
is, missense, nonsense, consensus splice site, and read-
through) variants. Details regarding quality control proce-
dures and read depth for case and control samples are
detailed in the Supplemental Material of Neale et al. [50].
Functional studies
Constructs
A full-length cDNA encoding human SERT in the mam-
malian expression vector pcDNA3.1 (Invitrogen, Carlsbad,
CA, USA) and a full-length cDNA encoding the human
A3AR (myc-A3AR/pCMV) have been described previ-
ously [30]. In vitro mutagenesis of the A3AR cDNA clone
to introduce Val90 and Ile171 variants were performed
using the QuikChange mutagenesis kit (Stratagene, La
Jolla, CA, USA). Variant constructs were later confirmed
by direct sequencing of the entire open reading frame.
Cell culture and transfection
Chinese Hamster Ovary (CHO) cells were maintained at
37°C in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum, 1% L-glutamine, 100 IU/mL
penicillin, and 100 μg/mL streptomycin. Transfections
were performed using the TransIT-CHO Transfection
reagent (Mirus, Madison, WI, USA). Quantities of
50 ng/well SERT and 20 ng/well of A3AR cDNAs were
preincubated with Mirus reagent for 30 min at room
temperature prior to adding to plated cells, seeded at
20,000 cells/well. Transfected cells were cultured for an
additional 24-48 h after transfection and prior to assay
of [3H]5-HT transport activities.
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The concentration of the second messenger cyclic gua-
nosine monophosphate (cGMP) was measured using the
CatchPoint cGMP fluorescent assay kit (Molecular
Devices, Sunnyvale, CA, USA). In brief, CHO cells co-
transfected with wildtype A3AR or A3AR coding vari-
ants and SERT cDNAs were plated at 50,000 cells/well.
Cells were initially washed in a Krebs-Ringer bicarbonate
(KRGB) prestimulation buffer containing 0.8 mM 3-
isobutyl-1-methylxanthine (IBMX), an inhibitor of cGMP-
phosphodiesterases. Following a 10 min incubation period,
cGMP accumulation was measured in response to a 1 μM
IB-MECA or vehicle treatment at various time points
(0 min, 10 min, 20 min, 30 min, 40 min, 60 min) according
to the manufacture’s protocol. The 1 μM IB-MECA con-
centration was selected on the basis of previous studies
[28,30] that found optimal stimulation of A3ARs under
those conditions. All values were normalized to 100%
representing basal (that is, time = 0 min) wildtype (WT)
cGMP levels. Statistical analyses comparing the effects of
IB-MECA treatment on variant and wildtype A3ARs were
performed with Prism (GraphPad, La Jolla, CA, USA)
using two-way analysis of variance (ANOVA). We used a
t-test to compare overall differences of IB-MECA treat-
ment on variant and wildtype A3ARs for cGMP synthesis
(and 5-HT below) over the full time course, area under the
curve (AUC) was calculated with Prism using total cGMP
production (or 5-HT uptake) for each 60 min time course
experiment. Means and standard errors of the mean were
calculated using each experiment. P values <0.05 were
considered significant.
5-HT transport assays
Assays measuring transport of [3H]5-HT were conducted
as described previously [28,30]. Briefly, medium from
CHO cells were removed and cells washed with Krebs-
Ringer-Hepes (KRH) buffer containing 130 nM NaCl,
1.3 nM KCL, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM
KH2P04, 1.8 g/L glucose, 10 mM HEPES, pH 7.4, 100 mM
pargyline, and 100 mM ascorbic acid. Cells were incu-
bated in triplicate at 37°C in KRH buffer containing
100 μM pargyline and 100 μM ascorbic acid, with and
without the adenosine A3 selective agonist and adenosine
analog IB-MECA. Following incubation with IB-MECA, a
10 min incubation with [3H]5-HT (20 nM) at 37°C was
performed, followed by aspiration of buffer and three
washes with ice-cold KRH buffer. Cells were then
solubilzed with 0.5 mL Microscint-20, and [3H]5-HT ac-
cumulation was quantified using a TopCount plate
scintillation counter (PerkinElmer Life and Analytical
Sciences, Waltham, MA, USA). Specific 5-HT uptake
was determined by subtracting the amount of [3H]5-HT
accumulated in the presence of 10 μM paroxetine, a select-
ive SERT inhibitor. A minimum of three independentreplicates were performed for each experiment. Analyses
comparing basal (time = 0 min) and IB-MECA-modified
uptake for wildtype vs. variant A3AR/SERTco-transfections
at individual time points and for the full time course was
calculated and plotted using Prism as described above.
Molecular modeling to predict location of A3AR coding
variants
The A3AR residue positions of Leu90 and Val171 were
determined for the human adenosine A2a receptor
(A2aAR) by amino acid sequence alignment and were
found to correspond to Val84 and Val171, respectively.
The relative positions and structural conformation of
the corresponding A2aAR residues were determined
using structural data obtained using an adenosine-
bound, thermostabilized A2aAR (PDB ID:Y2DO) as a




To test whether common alleles at ADORA3 contribute
to ASD risk, we genotyped a sample consisting of 958
autism families using four SNPs representing common
haplotypes that span the ADORA3 locus. Primary FBAT
analyses of genotype data were designed to test allelic
transmissions along two axes of stratification: strict vs.
spectrum diagnostic classifications and European vs. all
ancestries, yielding four primary analyses. Analysis for
each of the resulting four strata (strict-European and
strict-all ancestries; spectrum-European and spectrum-
all ancestries) showed no evidence to support common
variant association at ADORA3 using data for the four
SNPs tested (Additional file 3: Table S3). Analysis of
haplotypes (>5%) across the locus that were captured by
these SNPs also showed no significant association, con-
sistent with single marker analysis (data not shown).
Sequence-based discovery of functional variation at
ADORA3
To identify potentially functional, risk variants in
ADORA3, we screened all exons and the promoter re-
gion in 185 unrelated ASD cases and 305 non-clinical
comparison samples by direct Sanger sequencing. Com-
parison samples were selected to ethnically match case
samples for Caucasian and African-American subjects,
which represented the vast majority of the case screen-
ing panel (see Methods). Multiple synonymous and
non-synonymous variants were identified and are docu-
mented in Table 1. Three novel variants, two non-
synonymous (ns) and one synonymous, were detected in
cases (Leu90Val, Val171Ile, Cys194) but were not previ-
ously documented in dbSNP or 1000 Genomes (1 kG)
[51]. A novel Ala195Thr substitution was identified in a
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by sequencing independent PCR products included par-
ents and other siblings (when applicable). No de novo vari-
ants were detected, and thus all were inherited in ASD
families. Bioinformatic algorithms PolyPhen2 [45], SIFT
[46], and SNAP [47] that predict the likelihood of
functional effect of coding variants on protein function
were applied to rare (<1%) ns-variants identified. Val171Ile
(detected only in cases) was predicted to be ‘damaging’ or
‘not tolerated’, however, Leu90Val along with Ala195Thr
were predicted to be benign substitutions. We note that
subsequent to our discovery of novel Leu90Val and
Ile171Val variants, but during subsequent functional and
follow-up genetic experiments, both variants emerged
from 1 kG sequence data and were thus deposited into
dbSNP, as reflected in Table 1.
We sought to determine whether there was evidence
for an increase of rare ADORA3 coding variants in cases
compared with controls. Both Leu90Val and Val171Ile
were detected only in ASD cases and not controls (3/
370 case chromosomes for each variant vs. 0/562 control
chromosomes). A case-control comparison of these indi-
vidual rare alleles does not reach significance given the
small number of observations (Fisher’s Exact P=0.064 for
Leu90Val and Val171Ile each). Given the inherent limita-
tion in power to compare rates of single rare alleles, a
gene-wide discovery model suggests that a better approach
is to model all ‘functional’ (that is, non-synonymous, con-
sensus splice site, and read-through) rare variants simul-
taneously for case-control comparisons. Therefore, we
employed the Cohort Allelic Sums Test (CAST) to test for
an overall increased burden of rare (<1%) nsSNPs in
ADORA3 in ASD. We reasoned that any risk effect of
higher frequency, common coding variants would be
indexed by SNP and haplotype-based association studies
described above. Allele counts obtained from sequence dis-
covery in 185 cases and 305 controls were tabulated for
Leu90Val, Val171Ile, and Ala195Thr, and a Fisher’s Exact
test was conducted (Table 2). This analysis showed a sig-
nificant burden effect (6/185 ASD individuals vs. 1/310
controls; P=0.013; OR=10.19, CI = 1.20-81.56). We note
that, as described in Methods, we have low power to detect
rare variants of only modest risk effect. Nevertheless, we
observed a nominal increase in rare ‘functional’ variants in
the discovery case sample vs. controls, and this prompted
us to: (1) conduct functional studies of the novel variants
found in ASD cases for effects on SERT; and (2) subse-
quently compare the putative increase of rare, ‘functional’
variants in ASD cases to data from exome sequence that
became available from the NIH ARRA Autism Sequencing
Consortium [50,52]. Consistent with published data on ac-
cepted risk CNVs (for example, 16p11.2, 1q21.1, 22q11.2,
22q13.3, and so on) [53-55], novel variants Leu90Val and
Val171Ile did not always segregate to only (or all) affectedindividuals in a family, consistent with incomplete pene-
trance of these variants (Figure 1).
The availability of crystal structure for a human
ligand-bound adenosine A2a receptor (A2aAR) [56] pro-
vides an important source of structure-function informa-
tion that can inform predictions of a potential functional
impact of the Leu90Val and Ile171Leu variants. Figure 2
depicts the structure of the A2aAR, modeling the posi-
tions of residues equivalent to Leu90 and Val171 in A3AR,
in relation to bound adenosine. Our model predicts that
the A3AR residues Leu90 and Val171 flank the adenosine-
binding site, supporting a hypothesis that one or both of
these variants may affect A3AR function. Leu90 and
Val171 show consistent cross-species conservation in
mammals, while Ala195 is less conserved (Figure 3).
Functional studies therefore focused solely on the two
variants identified in cases.
Functional analysis of Leu90Val- and Val171Ile-A3AR
effects on cGMP production and SERT activity
To test for potential functional effects caused by the
Leu90Val and Val171Ile substitutions, we engineered hu-
man A3AR cDNA expression constructs to harbor either
Leu90Val or Val171Ile variants for experimentation in a
heterologous transfection system using CHO cells. In
prior studies, we have found that CHO cells support both
the investigation of A3AR regulation of SERT as well as
studies of A3AR/SERT physical association [29,30]. West-
ern blot analysis of cell lysates using an anti-myc probe
confirmed equivalent expression of myc-tagged wildtype
and both variant A3AR constructs, Leu90Val [29] and
Val171Ile (data not shown). We first asked whether either
variant (G-protein coupled) receptors produced increased
(or otherwise altered) levels of cGMP that might result
in a downstream increase of SERT activity. The human
A3AR and SERT constructs were co-transfected into
CHO cells, and we assessed basal cGMP levels for both
variants, and then following activation of receptors with
the A3AR selective agonist IB-MECA. Figure 4A (at
0 min) demonstrates that CHO cells co-transfected with
the Leu90Val variant display significantly elevated basal
cGMP compared to wildtype A3AR co-transfected cells
(L90V: 207.85% ± 45.71 vs. WT: 100.0% ± 0.02; P=0.015,
n=3). Stimulation of the Leu90Val A3AR by IB-MECA
(1 μM) revealed that the elevated cGMP production
seen in the basal state persisted over the full time course
and paralleled wildtype A3AR with both returning to
their respective basal states after 40 min (Figure 4A and
Additional file 4: Figure S1A; L90V: 163.3% ± 29.15 vs.
WT: 100.0% ± 6.32; 1-tailed t-test P=0.049, n=3).
In contrast with Leu90Val, cells co-transfected with
Val171Ile-A3AR/SERT displayed basal cGMP levels simi-
lar to those observed in wildtype A3AR co-transfected
cells (V171I: 116.1% ± 16.3 vs. WT: 100.0% ± 9.2, n=3).
Table 1 Sanger sequencing discovery of variation at ADORA3
Unrelated probands Caucasian controls African-American
controls
SNP ID HGVSa mRNA positionb
(NM_000677.3)
mRNA locationc Chromosomesd MAFe Chromosomesd MAFe Chromosomesd MAFe
rs10776728 c.108-13736A>T -376 105/370 0.284 178/562 0.317 17/48 0.354
rs140137165 c.108-13682G>C -322 0/370 0.000 0/562 0.000 2/48 0.042
c.108-13643G>T -283 0/370 0.000 1/562 0.002 0/48 0.000
rs10776727 c.108-13642G>T -282 164/370 0.443 251/562 0.447 13/48 0.271
rs114241928 c.108-13599C>G -239 0/370 0.000 0/562 0.000 2/48 0.042
c.108-13532C>T -172 1/370 0.003 0/562 0.000 0/48 0.000
c.108-13371C>T -11 0/370 0.000 2/562 0.004 0/48 0.000
c.-724G>A 44 5'UTR 1/370 0.003 1/562 0.002 0/48 0.000
rs1544223 c.-581G>A 187 5'UTR 71/370 0.192 119/562 0.212 11/48 0.229
rs1544224 c.-564 T>C 204 5'UTR 73/370 0.197 130/562 0.231 11/48 0.229
c.-563G>A 205 5'UTR 0/370 0.000 1/562 0.002 0/48 0.000
c.-479A>G 289 5'UTR 0/370 0.000 1/562 0.002 0/48 0.000
rs41282522 c.-221G>C 547 5'UTR 52/370 0.141 81/562 0.144 6/48 0.125
rs41282520 c.-105A>C 663 5'UTR 1/370 0.003 4/562 0.007 0/48 0.000
c.-85G>A 683 5'UTR 0/370 0.000 1/562 0.002 0/48 0.000
rs35789323 c.265C>T 1,032 Leu89Leu 1/370 0.003 0/562 0.000 0/48 0.000
rs77883500 c.268C>G 1,035 Leu90Val 3/370 0.008 0/562 0.000 0/48 0.000
rs76934313 c.345C>T 1,112 Thr115Thr 2/370 0.006 3/562 0.005 0/48 0.000
rs2789537 c.390C>T 1,157 Ala130Ala 6/370 0.016 5/562 0.009 1/48 0.021
rs139935750 c.511G>A 1,278 Val171Ile 3/370 0.008 0/562 0.000 0/48 0.000
c.582C>T 1,349 Cys194Cys 1/370 0.003 1/562 0.002 0/48 0.000
rs143962803 c.583G>A 1,350 Ala195Thr 0/370 0.000 1/562 0.002 0/48 0.000
rs35511654 c.742A>C 1,509 Ile248Leu 54/370 0.146 84/562 0.158 6/48 0.125
rs2800889 c.797 T>A 1,564 Met266Lys 6/370 0.016 5/562 0.009 1/48 0.021
rs2229155 c.897 T>C 1,664 Ala299Ala 52/370 0.154 100/562 0.178 9/48 0.188
c.*97C>A 1,821 3'UTR 0/370 0.000 1/562 0.002 0/48 0.000
rs923 c.*189C>T 1,913 3'UTR 51/370 0.149 100/562 0.178 9/48 0.188
rs1415793 c.*336C>T 2,060 3'UTR 51/370 0.149 100/562 0.178 9/48 0.188
rs75048140 c.*350A>G 2,074 3'UTR 2/370 0.005 0/562 0.000 0/48 0.000
rs1415792 c.*377A>G 2,101 3'UTR 50/370 0.146 100/562 0.178 9/48 0.188
c.*409C>T 2,133 3'UTR 0/370 0.000 1/562 0.002 0/48 0.000
rs3393 c.*423G>A 2,147 3'UTR 123/370 0.435 258/562 0.459 9/48 0.188
rs3394 c.*441A>G 2,165 3'UTR 51/370 0.149 99/562 0.176 9/48 0.188
aHuman Genome Variation Society (HGVS) recommended nomenclature. * Indicates substitution 3’ of termination codon.
bIndicates base-pair position within mRNA strucutre. RefSeq Accession number is given in parenthesis.
cIndicates location within mRNA structure (Exon). Negative (-) numbers indicate base pair position 5' to mRNA. Amino acid substitutions are shown relative to
protein position.
dIndicates the number of minor allele counts over the total number of chromosomes sequenced.
eMAF indicates minor allele frequency.
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transfections failed to show any stimulation of cGMP
production that was seen with wildtype A3AR. This
inability of the Val171Ile receptor to be stimulated by
IB-MECA appeared as a slightly diminished cGMP syn-
thesis over the time course compared with wildtype, al-
though this difference was not statistically significant(Additional file 4: Figure S1A; V171I: 90.14% ± 12.22 vs.
WT: 100.0% ± 16.18; 1-tailed t-test P=0.303, n=3).
The IB-MECA induced stimulation of cGMP produc-
tion in wildtype A3AR/SERT co-transfections displayed
in Figure 4A paralleled the expected stimulation of
SERT-mediated 5-HT uptake activity by wildtype A3AR
(Figure 4B and [30]). Although the elevation in peak 5-
Table 2 The Cohort Allelic Sums Test (CAST) on rare
ADORA3 variants in discovery cohort
rs# mRNA Cases Controls
rs77883500 Leu90Val 3 0
rs139935750 Val171Ile 3 0
rs143962803 Ala195Thr 0 1
Carriers 6 1
Non-carriers 179 304
P=0.013 (OR=10.19, CI: 1.22-85.37).
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co-transfections was not significantly greater than that
for wildtype A3AR (Figure 4B; L90V: 148.5% ± 7.1 vs.
WT: 140.3% ± 4.5; n=4), the IB-MECA-stimulated in-
crease in 5-HT uptake activity mediated by the variant
receptor persisted above that seen in cells transfected with
the wildtype receptor throughout the time of our observa-
tions. Indeed, the significantly increased 5-HT uptake,
seen at 40 min for Leu90Val A3AR transfected cells, the
time by which wildtype A3AR-stimulated SERT activity
had already returned to baseline levels (L90V: 131.3% ±
7.1 vs. WT: 108.3% ± 3.7; two-way ANOVA P=0.001, n=4)
did not return to wildtype levels until the next time point
measure, 20 min later (Figure 4B). These observations re-
flect an overall greater 5-HT uptake in Leu90Val-A3AR
cells compared to wildtype A3AR (Additional file 4:
Figure S1B; L90V: 112.2% ± 8.80 vs. WT: 100.0% ± 3.22;
1-tailed t-test P=0.020, n=4).
In striking contrast to the enhanced SERT activity ob-
served with Val90 co-transfected cells, IB-MECA treat-
ment of Ile171, compared with wildtype co-transfectedFigure 1 Pedigree structure of ASD families harboring the Leu90Val o
by an asterisk. Individuals for whom DNA was not available are labeled NA
unfilled elements reflect individuals without an ASD diagnosis.cells failed to stimulate SERT activity (Figure 4C) across
all agonist doses tested (for example, 1 μM IB-MECA
Val171Ile: 101.8% ± 12.5 vs. WT: 136.3% ± 7.2; two-way
ANOVA P=0.005; n=3-4).Replication test of an increased rate of rare functional
variants in cases vs. controls
With support from both initial Sanger discovery experi-
ments and subsequent functional studies that potentially
ASD-related, functional variation had been identified in
ADORA3, we sought replication of the putative increase
of such variants in ASD cases vs. controls. We examined
whole exome sequence data from 339 cases and pair-
matched controls of European ancestry generated by the
NIH ARRA Autism Sequencing Consortium [50] for the
presence of functional variants at ADORA3 (see methods
for exclusion criteria). Nine non-synonymous and nu-
merous synonymous variants were discovered in these
pair-matched samples that were completely independent
from the discovery sample. In total, nine of 12 subjects
harboring non-synonymous variants were detected in
cases, and the remaining three in controls (9/339 ASD
individuals vs. 3/339 controls); although that relative
increase was not statistically significant (Fisher’s Exact 1-
tailed P=0.071; OR = 3.06, CI: 0.82-10.99; Table 3). Spe-
cifically, Leu90Val was found in one additional case and
no controls, while Val171Ile was found in two additional
cases but also one control. Of the remainder, four add-
itional missense variants (Ile22Thr, Phe48Ser, Ala69Ser,
and Leu294Thr) were found in one case each and no
controls, and a single read-through mutation (*319Gln)
predicted to add an additional 38 residues (>10% of ther Val171Ile variants. Subjects harboring either variant are indicated
. Individuals with ASD are indicated by filled circles or squares, while
Figure 2 Structure of the A2a adenosine receptor identifying corresponding positions of Leu90 and Val171 residues in the A3
receptor. The structure of the thermostabilized A2a receptor, A2aAR-GL31 (PDB code 2YDO), is depicted as a cartoon in rainbow coloration (N-
terminus in blue, C-terminus in red), viewed either (a) parallel to the membrane plane or (b) from the extracellular surface perpendicular to the
membrane plane. The endogenous ligand adenosine is shown as a stick model (C, yellow, N, blue, O, red) as is the side chain for Phe168 (C,
green). The transmembrane helices are labeled H1-H7, the extracellular loop 2 (EL2) is indicated and H8 is the C-terminal amphipathic helix lying
parallel to the membrane plane. A3AR residues Leu90 and Val171 correspond to Val84 and Val171 in A2aAR, and they are both shown as space-
filling models (grey).
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Two additional missense variants were detected in con-
trols (Phe180Leu and Ala273Thr). Each of these variantspassed stringent quality control thresholds and have
read-depths that, based on empirical data, have an ex-
tremely high positive predictive value for being valid calls
Figure 3 Cross-species conservation at ADORA3 variant sites detected by Sanger sequencing. Amino acid sequences of the A3AR protein
encoded by ADORA3 are aligned for the three variants and their flanking residues: Leu90Val, Val171Ile (cases), and Ala195Thr (controls).
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dated. Prediction of functional consequences using
PolyPhen2 [45] indicated that two missense variants were
forecast to be benign (Ala69Ser and Leu294Thr) and four
missense to be damaging (Ile22Thr, Phe48Ser, Phe180Leu,
and Ala273Thr). Combining both discovery and replica-
tion findings strengthens evidence for an increase of
‘functional’ variants in ASD, with counts of 15 of 524 cases
compared with four of 644 controls harboring such variants
(Fisher’s Exact 1-tailed, Bonferroni-corrected P=0.0025;
OR = 4.72, CI: 1.56-14.30). Moreover, taking into account
replication data, the enrichment of Leu90Val in ASD cases
vs. controls becomes statistically significant (Fisher’s Exact 1-
tailed P=0.040; 4/1,048 ASD vs. 0/1,288 control chromo-
somes). Although present in greater numbers in ASD cases,
enrichment for Leu171Ile by itself did not reach significance
(Fisher’s Exact 1-tailed P=0.068; 5/1,048 ASD vs. 1/1,288
controls).Exploring phenotypic and genomic characteristics of
ADORA3 variant carriers
We explored the possibility that dimensions of the ASD
phenotype might stand out in affected carriers of Val90
and Ile171 or other ADORA3 variants. We examined do-
main and item-level data from the ADI-R to explore the
possibility that certain ASD features might be more pro-
nounced in ADORA3 rare variant-carriers. Such compari-
sons are inherently limited by a small number of carriers
relative to hypothetical phenotypic effect sizes and different
mechanistic effects on A3AR for a given variant. Our
examination of available data showed no consistent
pattern of elevated or diminished ADI-R domain scores in
carriers vs. non-carriers (Additional file 5: Table S4). We
found a similar lack of correlation upon examination of
ADI-derived principal components analysis-derived scores
[57]), as a complementary set of dimensional ASD traits
(data not shown).
Figure 4 Functional consequences of the A3AR specific agonist
IB-MECA on WT-A3AR and Leu90Val-A3AR or Val171Ile-A3AR
expressing cells. CHO cells co-transfected with either WT-A3AR or
Leu90Val-A3AR or Val171Ile-A3AR and SERT and were stimulated
using IB-MECA (1 μM). (A) Levels of cGMP production from WT-
A3AR/SERT and Leu90Val-A3AR/SERT co-transfections were
measured prior to and after IB-MECA stimulation. Leu90Val-A3AR/
SERT cells display elevated basal cGMP production that persists over
the entire 60 min time course experiment, revealing enhanced
overall production of cGMP (1 tailed t-test P=0.049; n=3). Each of the
three independent experiments contained a minimum of three
internal replicates. (B) 60 min time-course of IB-MECA induced 5-HT
uptake as measured as percent of control (wildtype; time = 0 min).
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also harbored other known or likely risk factors, we
examined data from published work describing CNVs in
respective samples [58,59]. Some inherited CNVs were
identified in the six cases for which CNV data were avail-
able; for the remaining nine samples, CNV data were not
available and several of these have not been subjected
to array based genotyping or analysis. Most CNVs
corresponded to regions also detected in controls, how-
ever, a single de novo duplication of approximately 211 kb
(hg18: ChrX:153263157–153474401) was found in theCHO cells were co-transfected with either wildtype-A3AR and SERT
or Leu90Val-A3AR and SERT, and 5-HT uptake was stimulated using
IB-MECA (1 μM). Cells were incubated with [3H]5-HT (20 nM) for the
indicated period. Over the time course (0-60 min) in Leu90Val-A3AR/
SERT expressing cells, 5-HT uptake is elevated compared with the
wildtype A3AR counterpart (1 tailed t-test, P=0.039; n=4). Each
independent experiment contained a minimum of three internal
replicates. (C) [3H]5-HT accumulation in cells co-transfected with
A3AR and human SERT was measured, and indicate a failure of
IB-MECA treatment of Val171Ile-A3AR/SERT to induce SERT
dependent 5-HT re-uptake across all tested concentrations.
Compared to the peak concentrations (0.8 μM and 1.0 μM) of IB-
MECA induced 5-HT uptake in WT-A3AR/SERT, IBMECA induced 5-HT
uptake was significantly reduced (for example, 1 μM IB-MECA
Val171Ile: 101.8% ± 12.5 vs. WT: 136.3% ± 7.2; two-way ANOVA
P=0.005; n=3-4). Significant (P <0.05) findings are indicated by an
asterisk (*).male proband (NIMH ID: 217-14216-3470) harboring a
Ala69Ser substitution in ADORA3.
Discussion
Based upon our knowledge that SERT and 5-HT have a
longstanding connection to ASD, that A3AR plays a key
role in SERT regulation via PKG and p38 MAPK signaling
pathways, and that SERT is an essential regulator of 5-HTTable 3 The Cohort Allelic Sums Test (CAST) on rare
ADORA3 variants in replication cohort
rs# mRNA Cases Controls
rs112045912 Ile22Thr 1 0
Phe48Ser 1 0
Ala69Ser 1 0
rs77883500 Leu90Val 1 0




rs112042574 *319Gln 2 0
Carriers 9 3
Non-carriers 330 336
* Indicates termination codon.
P=0.071 (OR=3.06, CI: 0.82-11.39).
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ASD-associated alleles. Our experiments were premised on
a specific hypothesis: functional risk variants at ADORA3
would lead to a signaling-mediated elevation of SERT-
dependent 5-HT uptake activity, phenocopying in vitro the
elevated function seen with rare, ASD-associated SERTcod-
ing variants [17,20,23]. Regarding association of ASD with
SERT variants, we note that sequencing of SLC6A4 by an-
other group testing unrelated ASD probands from singleton
or multiplex families (and controls) but without obligate al-
lele sharing (linkage) at 17q11.2 did not show a similar pat-
tern of enriched coding variants, and thus association with
ASD risk [60]. We believe therefore that screening of multi-
plex probands with allele sharing in this region was an im-
portant factor in our initial discovery of novel, functional
variants, given the extreme genetic heterogeneity under-
lying ASD. Moreover, results from genotyping of ASD and
related cohorts by Delorme and colleagues [20,21] further
support ASD association initially suggested by Ozaki et al.
[20,21] and reinforced by our own studies.
Consistent with results from large-scale GWA scans
for common allele susceptibility effects [35,43], we found
no evidence to support a main effect on ASD association
attributable to common variants at ADORA3. The current
study is limited in power to detect alleles of small effect size
(for example, OR <1.3), so we cannot exclude the possibility
that common ADORA3 variants confer very small effect
sizes or interact with alleles at other genes to confer risk.
Mechanistically, we anticipated that a more likely sce-
nario was for ADORA3 to harbor coding variants, likely
rare, that might impact A3 function directly and SERT
function indirectly. Numerous, recent studies focused on
CNV or sequencing [44,50,58,61-64] have documented
that rare variation affecting a large number of genes is
collectively a major source of genetic liability in autism.
Our results are consistent with ADORA3 being one such
gene that contributes to ASD liability in rare cases. Here,
we present the identification of novel coding variants in
ADORA3 in a Sanger sequencing-based screen of cases
and non-clinical comparison samples ethnically matched
to the case sample. This screen showed a statistically sig-
nificant increase in coding variants in cases vs. controls
(P=0.013). Subsequent availability and analysis of exome
sequence data from cases and clinically-screened con-
trols [50] showed a greater number of ‘functional’ vari-
ants at ADORA3 in cases compared with controls (15/
524 vs. 4/644), but a difference that was not significant
(P=0.07). Nevertheless, combining Sanger discovery and
newly available exome sequence data strengthens evidence
for association, even after Bonferroni correction for
multiple comparisons (Fisher’s exact 1-tailed P=0.0025;
OR = 4.72, CI: 1.56-14.30).
Encouraged by the initial discovery of Leu90Val and
Val171Ile, functional studies focused on these two rarenon-synonymous variants identified from the ASD discov-
ery sample. To test our central SERT regulatory network
hypothesis, analysis of Leu90Val and Val171Ile examined
the effect of receptor stimulation to induce cGMP synthe-
sis via G-protein coupling and on downstream SERT-
dependent 5-HT uptake. IB-MECA stimulation of the
Val90-encoded A3AR showed enhanced cGMP synthesis
compared with wildtype A3AR under basal conditions, and
enhanced cGMP levels extended over the full time course
ending with a return to the elevated baseline. These results
mirrored our findings that the IB-MECA induced increase
in SERT-dependent 5-HT uptake activity across the experi-
mental time course including a delayed return to baseline
in co-transfections with the Leu90Val mutant A3 receptor
compared with wildtype A3AR. Thus, overall 5-HT uptake
is significantly increased in cells expressing the mutant A3
receptor. Increases in both cGMP and 5-HT uptake activ-
ity parallels our recent report of enhanced Leu90Val-
A3AR/SERT complex formation [29], which implies (1)
enhanced basal receptor-G protein coupling, (2) reduced
receptor desensitization, and/or possible differences in the
binding kinetics of IB-MECA to Val90-A3AR as a conse-
quence of its location proximal to the A3AR ligand bind-
ing site upon agonist stimulation. Taken together, our
results are consistent with our prior expectation, based on
increased 5-HT uptake caused by rare autism-associated
coding mutations in SERT [17,20,23]. In particular, the
Gly56Ala SERT variant, exhibited increased catalytic activ-
ity as would be achieved through stimulation by PKG and
p38 MAPK signaling, which represent the primary path-
ways for A3AR-mediated upregulation of SERT.
In contrast to Leu90Val, the Val171Ile variant rendered
A3AR insensitive to the selective IB-MECA agonist to in-
duce increased cGMP synthesis and a downstream increase
in SERT-dependent 5-HT uptake activity. The molecular
mechanism underlying this effect is not yet clear, however,
we postulate that the proximity of the Val171 residue to the
ligand binding pocket may prevent or hinder the ability of
the adenosine analog IB-MECA to bind A3AR, resulting in
a more rapid dissociation and/or less efficient (or absence
of) receptor-G protein coupling. Additional experiments will
be required to fully elucidate the molecular mechanisms of
these two coding variants on receptor function. Although
the functional impact on SERT of the Leu90Val and
Val171Ile variants are in opposite directions, it is possible
that both elevated and diminished capacity for regulation of
SERT through A3AR pathways can impact 5-HT clearance
in a manner that disrupts 5-HT’s ability to coordinate brain
development [65,66] and/or adult 5-HT signaling [67,68].
We initially conceptualized dysregulation of a SERT
regulatory network based not only on the molecular im-
pact ASD-associated SERT mutations, rather within a
broader context that implicates disruptions in 5-HT sig-
naling in autism. Hyperserotonemia in 35% of ASD cases
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example, fluoxetine, citalopram) and atypical antipsy-
chotics (for example, risperidone) in ameliorating irritabil-
ity and other anxiety-related problems in ASD are just
two of many themes that implicate 5-HT dysregulation in
ASD. We previously demonstrated a proof-of-principal
for genetic variation in SERT-binding and regulatory
proteins being associated with ASD. Here we refer to the
common Leu33Pro variant in ITGB3, which has been
statistically associated with both elevated 5-HT levels in
blood [9] and ASD risk [69], and which causes allele-
dependent effects on SERT activity and regulation [70].
We recently observed hyperserotonemia in a knock-in
mouse model of the Gly56Ala SERT variant, along with
p38 MAPK-dependent hyperphosphorylation of SERT,
increased SERT-dependent 5-HT clearance and 5-HT re-
ceptor hypersensitivity in vivo, as well as social behavior
impairments, repetitive behaviors, and deficits in commu-
nication [25]. Nonetheless, we recognize that statistical as-
sociation of rare ADORA3 variants (especially Leu90Val)
requires further validation in larger samples. This is the
case for rare variants in any specific locus implicated in
ASD, and has led many investigators to emphasize the
network as a better substrate to elucidate the underlying
mechanisms. We recognize that the magnitude of ASD
risk conferred by these variants is unknown. Indeed, the
single male case harboring an Ala69Ser variant (of un-
known functional effect) at ADORA3 also possessed a de
novo duplication of an X-linked interval including RPL10,
a gene for which inherited and de novo point mutations
and gene-disrupting and/or CNV deletion has been asso-
ciated with ASD and ID [71]. Duplication effects here are
unknown, but this variant is likely to confer risk. Never-
theless, we believe these studies will add to the growing
body of data implicating specific gene/protein networks in
contributing to ASD liability. Taken together our studies
support the case for 5-HT and more specifically SERT
regulatory pathways as one gene/protein network in which
perturbations contribute to the underlying pathophysi-
ology of ASD. Further studies within this network may
provide new leads to ASD therapeutics.
There are a few limitations or caveats of the studies
we present. First, while the discovery sequence sample
was ethnically matched, subjects were not matched
based on genome-wide genotype data. It is possible
therefore, that subtle population stratification effects
could lead to inflation of the observed increase in num-
bers of rare, ‘functional’ variants in cases vs. controls.
Given that the case and control samples from the AASC
were pair-matched based on genotype data, and the
greater number of functional variants in those cases
(15/524 vs. 4/644) was not statistically significant in a
Fisher’s Exact test, we recognize that both discovery
(P=0.0143) and combined (P=0.0025) evidence for gene-based association of rare, ‘functional’ variants should be
interpreted with caution. Second, while multiple com-
parisons were conducted in functional experiments, we
are reassured that the increases in cGMP production
and 5-HT uptake parallel one another, supporting our
conclusions regarding the ability of Leu90Val A3AR to
augment SERT-dependent 5-HT uptake over time. Fi-
nally, we note that the functional experiments were
conducted in CHO cells, and may not reflect the func-
tion during or after development in vivo. While this is
certainly possible, our study of multiple variants in
SERT and other proteins that influence SERT regulation
(for example, ITGB3) present a consistent picture of re-
sults from in vitro transfection-based experiments ul-
timately relating very well to effects on SERT function
in mouse models harboring these variants [70,72,73].
Conclusions
Our results validate the hypothesis that the SERT
regulatory network harbors rare, functional variants that
impact SERT activity and regulation in ASD, and encour-
ages further investigation of this network as a site for add-
itional functional variation that may impact ASD risk.Additional files
Additional file 1: Table S1. Characteristics of genotyped families with
autism stratified by ancestry. A total of 958 families were genotype for
common variants (MAF >5%). Ancestral background was determined
using classical multidimensional scaling (MDS) using PLINK.
Additional file 2: Table S2. Primers designed in Sanger sequencing
discovery of the ADORA3 gene loci.
Additional file 3: Table S3. Association analysis of common variants in
the ADORA3 gene loci. Analysis was conducted using the family-based
association test (FBAT) suite and genotype data generated from TaqMan
allelic discrimination assays in a sample of 940 autism families. SNP ID,
alleles, minor allele frequency (MAF), informative families, observed and
expected transmission counts, and corresponding P values (empirical
variance ‘-e’ option) are provided. Significant P values indicated evidence
for distortion of allele transmission.
Additional file 4: Figure S1. Activation of Leu90Val-A3AR expressing
cells leads to prolonged cGMP production and 5-HT uptake. (A) CHO cells
co-transfected with either WT-A3AR or Leu90Val-A3AR or Val171Ile-A3AR
and SERT and were stimulated using IB-MECA (1 μM). Leu90Val-A3AR/SERT
cells display elevated area under the curves (AUC) for cGMP production
compared to wildtype-A3AR/SERT. (B) IB-MECA induced Leu90Val-A3AR
activation enhances total SERT dependent 5-HT uptake compared to
wildtype. Significant (P <0.05) findings are indicated by an asterisk (*).
Additional file 5: Table S4. Autism phenotypic profile of rare variants
in the ADORA3 gene. Ancestry (AA: African American, EUR: European); IQ
(Composite score on the Wechsler Preschool and Primary Scale of
Intelligence (WPPSI) test); The Western Psychological Services (WPS)
domain scores of the Autism Diagnostic Interview-Revised are provided.
*: AGP ID, no NIMH ID available.
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buffered saline; PCR: Polymerase chain reaction; PKC: Protein kinase C;
PKG: Protein kinase G; SERT, SLC6A4: serotonin transporter.
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